Singapore - engelsk - HSA (Health Sciences Authority)

covidien private limited - general & plastic surgery - the versaone™ fascial closure system optical trocar with fixation cannula is intended for use in a variety of minimally invasive gynecologic, general, and urologic procedures to create and maintain a port of entry for laparoscopic instruments.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

life systems medical pty ltd - 46448 - fascial tissue dilator, single-use - composed of high-strength and flexible plastic sheaths can be used individually or telescopically for the extraction of implanted leads. each sheath has a colour that allows its immediate identification based on the diameter. the sheaths are marked with a radiopaque material in order to be clearly visible under fluoroscopy. extra safe sheaths are intended for use in patients requiring the percutaneous dilation of tissue surrounding cardiac leads, indwelling catheters and foreign objects.

USA - engelsk - NLM (National Library of Medicine)

american health packaging - sirolimus (unii: w36zg6ft64) (sirolimus - unii:w36zg6ft64) - sirolimus 0.5 mg - sirolimus tablets are indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants. in patients at low- to moderate-immunologic risk, it is recommended that sirolimus tablets be used initially in a regimen with cyclosporine and corticosteroids; cyclosporine should be withdrawn 2 to 4 months after transplantation [see dosage and administration ( 2.2)]. in patients at high-immunologic risk (defined as black recipients and/or repeat renal transplant recipients who lost a previous allograft for immunologic reason and/or patients with high panel-reactive antibodies [pra; peak pra level > 80%]), it is recommended that sirolimus tablets be used in combination with cyclosporine and corticosteroids for the first year following transplantation [see dosage and administration ( 2.3), clinical studies ( 14.3)]. cyclosporine withdrawal has not been studied in patients with banff grade 3 acute rejection or vascular rejection prior to cyclosporine withdrawal, those who are

Singapore - engelsk - HSA (Health Sciences Authority)

pfizer private limited - (active filler coat) sirolimus @ 100% - tablet, sugar coated - 2.0 mg - (active filler coat) sirolimus @ 100% 2.0 mg

Singapore - engelsk - HSA (Health Sciences Authority)

pfizer private limited - (active filler coat) sirolimus @ 100% - tablet, sugar coated - 1.00 mg - (active filler coat) sirolimus @ 100% 1.00 mg

USA - engelsk - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - sertraline hydrochloride (unii: uti8907y6x) (sertraline - unii:quc7nx6wmb) - sertraline 50 mg - zoloft (sertraline hydrochloride) is indicated for the treatment of major depressive disorder in adults. the efficacy of zoloft in the treatment of a major depressive episode was established in six to eight week controlled trials of adult outpatients whose diagnoses corresponded most closely to the dsm-iii category of major depressive disorder (see clinical trials under clinical pharmacology). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. the antidepressant action of zoloft in hospitalized depressed patients has not been adequately st

USA - engelsk - NLM (National Library of Medicine)

novitium pharma llc - sirolimus (unii: w36zg6ft64) (sirolimus - unii:w36zg6ft64) - sirolimus oral solution is indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants.  in patients at low-to moderate-immunologic risk , it is recommended that sirolimus oral solution be used initially in a regimen with cyclosporine and corticosteroids; cyclosporine should be withdrawn 2 to 4 months after transplantation [see dosage and administration (2.2)].   in patients at high-immunologic risk (defined as black recipients and/or repeat renal transplant recipients who lost a previous allograft for immunologic reason and/or patients with high panel-reactive antibodies [pra; peak pra level > 80%]), it is recommended that sirolimus oral solution be used in combination with cyclosporine and corticosteroids for the first year following transplantation [see dosage and administration (2.3), clinical studies (14.3)]. cyclosporine   withdrawal   has not been studied in patients with banff grade  3 acute rejection or   vascular rejection prior to cyclosporine

Singapore - engelsk - HSA (Health Sciences Authority)

pfizer private limited - (active filler coat) sirolimus - tablet, sugar coated - (active filler coat) sirolimus 0.5 mg

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - vemurafenib, quantity: 800 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; croscarmellose sodium; titanium dioxide; magnesium stearate; iron oxide red; hyprolose; purified talc; polyvinyl alcohol; macrogol 3350 - zelboraf is indicated for the treatment of unresectable stage iiic or stage iv metastatic melanoma positive for a braf v600 mutation.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

universal specialities ltd trading as usl medical - ethyl nicotinate 2%{relative}; hexyl nicotinate 2%{relative}; thurfyl salicylate 14%{relative} - topical cream - active: ethyl nicotinate 2%{relative} hexyl nicotinate 2%{relative} thurfyl salicylate 14%{relative} excipient: cetostearyl alcohol methyl hydroxybenzoate 3679e + terpineol + phenylethyl alcohol + spike lavendar oil polysorbate 20 purified water sorbitan stearate stearic acid